Keyword: Xiidra

Takeda HQ

10. Novartis/Takeda's Xiidra

Selling Shire’s legacy dry eye drug Xiidra to Novartis is one of several divestitures Takeda inked in 2019 to pare down the huge debt load incurred in its $59 billion takeover of the rare disease giant.
People shaking hands across a desk that has computer and papers on it

The top 10 largest biopharma M&A deals in 2019

Biopharma M&A got a big boost moneywise in 2019. The three largest delivered more than $150 billion, with Bristol-Myers Squibb's $74 billion takeover of Celgene setting a new record. Oncology was still a hot theme, stringing through a whole year of big dealmaking headlines, just as gene therapy gained popularity.